Sector pending / Biological Products, Except Diagnostic SubstancesUpdated 2026-05-10 22:07 UTC

FRA/1U5 stock hub

FRA/1U5 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/1U5is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.2B

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/1U5FRA/1U5

—

Loading chart…

In the news

Latest news · FRA/1U5

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-53.1

P25 n/aP50 n/aP75 n/a

ROIC-33.7

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/1U5 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

159

Groups with data

Currency

USD

Showing 159 of 159 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Singapore
Country code	DE
Employees	317
Employees Change	20%
Employees Change Percent	7.46
Enterprise value	EUR 724.2M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Biological Products, Except Diagnostic Substances
Last refreshed	2026-05-10
Market cap	EUR 1.2B
Price	EUR 5.9
Price currency	EUR
Rev Per Employee	196,436.61x
Sic	2836
Symbol	fra/1U5
Website	https://wavelifesciences.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.57%
EV Earnings	-4.55x
EV/FCF	-4.51x
EV/Sales	11.87x
FCF yield	-13.67%
P/B ratio	2.64x
P/S ratio	18.85x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-274.21%
EBITDA Margin	-269.47%
Gross margin	-164.07%
Gross Profit	EUR -102.2M
Net Income	EUR -159.2M
Pretax Margin	-255.7%
Profit Margin	-255.7%
Profit Per Employee	EUR -502,287
ROA	-28.23
Roa5y	-31.91
ROCE	-36.89
ROE	-53.11
Roe5y	-2,338.2
ROIC	-33.68

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	8.26%
Cagr3y	19.7%
Cagr5y	3.15%
Revenue Growth	-31.58x
Revenue Growth Q	316.85x
Revenue Growth3 Y	69.18x
Revenue Growth5 Y	35.16x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.16
Assets	EUR 506.1M
Cash	EUR 472.3M
Current Assets	EUR 475.9M
Current Liabilities	EUR 42.3M
Debt	EUR 13.6M
Debt Equity	EUR 0.03
Debt FCF	EUR -0.08
Equity	EUR 443.8M
Liabilities	EUR 62.3M
Long Term Assets	EUR 30.2M
Long Term Liabilities	EUR 20M
Net Cash	EUR 458.7M
Net Cash By Market Cap	EUR 39.09
Net Cash Growth	140.97%
Net Debt Equity	EUR -1.03
Tangible Book Value	EUR 443.8M
Tangible Book Value Per Share	EUR 2.31

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	11.26
Net Working Capital	EUR -21.5M
Quick ratio	10.93
Working Capital	EUR 443.6M
Working Capital Turnover	EUR 0.18

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-21.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	8.26%
200-day SMA	8.44
3Y total return	71.51%
50-day SMA	8.09
50-day SMA vs 200-day SMA	50under200
5Y total return	16.79%
All Time High	46.7
All Time High Change	-87.37%
All Time High Date	2018-09-25
All Time Low	1.1
All Time Low Change	436.36%
All Time Low Date	2022-05-16
ATR	0.29
Ch YTD	-60.14
High	5.9
High52	17.8
High52 Date	2025-12-10
High52ch	-66.85%
Low	5.9
Low52	4.8
Low52 Date	2026-03-26
Low52ch	22.92%
Ma50ch	-27.04%
Price vs 200-day SMA	-30.09%
RSI	41.1
RSI Monthly	46.84
RSI Weekly	40.33
Sharpe ratio	0.65x
Sortino ratio	1.5
Total Return	-21.45%
Tr YTD	-60.14
Tr1m	0.85%
Tr1w	-0.84%
Tr3m	-43.81%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -170.8M
Operating margin	-274.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	90,472,141%
Shares Insiders	0.4%
Shares Institutions	66.56%
Shares Qo Q	11.11%
Shares Yo Y	21.45%
Short Ratio	3.11

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -185.7M
Average Volume	74.55x
Bv Per Share	2.31
CAPEX	EUR -859,494
Ch1m	0.85
Ch1w	-0.84
Ch1y	8.26
Ch3m	-43.81
Ch3y	71.51
Ch5y	16.79
Ch6m	-9.92
Change	0%
Change From Open	0
Close	5.9
Days Gap	0
Depreciation Amortization	2,888,158.6
Earnings Date	2026-04-28
EBIT	EUR -170.8M
EBITDA	EUR -167.8M
EPS	EUR -0.89
F Score	1
FCF	EUR -160.4M
FCF EV Yield	-22.16x
Financing CF	422,034,251
Fiscal Year End	December
Founded	2,012
Investing CF	-859,494
Is Primary Listing	0
Last Earnings Date	2026-04-28
Last Report Date	2026-03-31
Ma150	8.98
Ma150ch	-34.27%
Ma20	5.99
Ma20ch	-1.42%
Net CF	261,542,121
Next Earnings Date	2026-08-03
Open	5.9
Ppne	15,323,521.3
Price Date	2026-05-08
Ptbv Ratio	2.64
Relative Volume	13.41x
Revenue	62,270,405x
SBC By Revenue	40.51x
Share Based Comp	25,223,686
Tr6m	-9.92%
Volume	0
Z Score	10.22

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/1U5 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/1U5 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/1U5?

Insider, institutional, and short-interest positioning.

Institutional ownership

+66.6%

Share of float held by funds and institutions

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

FRA/1U5 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

41.1

Neutral momentum band

Price vs 200-day MA

-30.1%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

0.65

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/1U5

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/1U5 stock rating?

fra/1U5 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/1U5 analysis?

The full report lives at /stocks/fra/1U5/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/1U5?

The latest report frames fra/1U5 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/1U5 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.